Search results
Showing 31 to 45 of 47 results for rivaroxaban
Research into the long-term treatment effects of rivaroxaban is needed.
Question Research into the long-term treatment effects of rivaroxaban is needed. Any explanatory notes(if applicable) None. Source
TA287/1 Question There have been no head-to-head trials of rivaroxaban compared with a low molecular weight heparin for people who have...
management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or...
Question Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients...
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
NICE recommends rivaroxaban to prevent blood clots in patients who have had a heart attack
Rivaroxaban (Xarelto), in combination with clopidogrel and aspirin, or with aspirin alone, can now be used as an option for preventing blood clots in people who have had an acute coronary syndrome, following latest guidance.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
Novel oral anticoagulants an option for patients with atrial fibrillation
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)
This evidence summary has been replaced by NICE technology appraisal guidance 335
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.
Patients with atrial fibrillation can now be offered rivaroxaban (Xarelto), as an alternative to warfarin, in order to reduce their risk of stroke and blood clots, says NICE.
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after total hip or total knee replacement in adults.